TY - JOUR
T1 - European consensus conference on faecal microbiota transplantation in clinical practice
AU - Cammarota, Giovanni
AU - Ianiro, Gianluca
AU - Tilg, Herbert
AU - Rajilić-Stojanović, Mirjana
AU - Kump, Patrizia
AU - Satokari, Reetta
AU - Sokol, Harry
AU - Arkkila, Perttu
AU - Pintus, Cristina
AU - Hart, Ailsa
AU - Segal, Jonathan
AU - Aloi, Marina
AU - Masucci, Luca
AU - Molinaro, Antonio
AU - Scaldaferri, Franco
AU - Gasbarrini, Giovanni Battista
AU - Lopez-Sanroman, Antonio
AU - Link, Alexander
AU - De Groot, Pieter
AU - De Vos, Willem M.
AU - Högenauer, Christoph
AU - Malfertheiner, Peter
AU - Mattila, Eero
AU - Milosavljević, Tomica
AU - Nieuwdorp, Max
AU - Sanguinetti, Maurizio
AU - Simren, Magnus
AU - Gasbarrini, Antonio
PY - 2017
Y1 - 2017
N2 - Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.
AB - Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.
KW - CLINICAL DECISION MAKING
KW - DIARRHOEAL DISEASE
KW - ENTERIC BACTERIAL MICROFLORA
KW - CLINICAL DECISION MAKING
KW - DIARRHOEAL DISEASE
KW - ENTERIC BACTERIAL MICROFLORA
UR - http://hdl.handle.net/10807/92029
U2 - 10.1136/gutjnl-2016-313017
DO - 10.1136/gutjnl-2016-313017
M3 - Article
SN - 0017-5749
SP - gutjnl-2016-313017-N/A
JO - Gut
JF - Gut
ER -